EUVIMEDEUVIMED entdecken
Crossref

Guillain–Barré syndrome

Sonja E Leonhard, Nowshin Papri, Luis Querol, Simon Rinaldi, Nortina Shahrizaila, Bart C Jacobs

Nature Reviews Disease Primers · 19.12.2024 · 10 (1)

DOI: 10.1038/s41572-024-00580-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature Reviews Disease Primers, online erschienen am 19.12.2024. Verfasst von Sonja E Leonhard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Infectious Disease, Erasmus MC, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 230 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guillain-Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy. Patients typically develop rapidly progressive weakness and sensory deficits that can result in complete paralysis requiring mechanical ventilation. GBS is usually a monophasic disease in which an aberrant immune response to an infection or other trigger damages the peripheral nerves. For example, in patients with preceding Campylobacter jejuni infection, molecular mimicry causes a cross-reactive antibody response to nerve gangliosides. Diagnosis is based on clinical features, supported by cerebrospinal fluid analysis and nerve conduction studies. Effective treatments include plasma exchange and intravenous immunoglobulins. However, ~20% of patients who received treatment are unable to walk after 6 months and ~5% die as a consequence of GBS. Important knowledge gaps in GBS include its pathogenesis, especially after viral infections. In addition, there is a lack of specific biomarkers to improve the diagnosis, monitor the disease activity, and predict the clinical course and outcome of GBS. Major challenges for the future include finding more effective and personalized treatments, which are affordable in low-income and middle-income countries, and preparation for outbreaks of infections as potential triggers for GBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Guillain-Barre SyndromeHumansCampylobacter jejuniImmunoglobulins, IntravenousPlasma Exchange

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • Department of Clinical Microbiology and Infectious Disease, Erasmus MC, Rotterdam, The Netherlands.
  • Laboratory of Gut-Brain Axis, Infectious Diseases Division (IDD), icddr,b, Dhaka, Bangladesh.
  • Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Neuromuscular Unit, Department of Neurology, Hospital de la Santa Creu i Santa Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red para Enfermedades Raras, CIBERER, Madrid, Spain.
  • Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Zitieren

APA

Leonhard, S. E., Papri, N., Querol, L., Rinaldi, S., Shahrizaila, N., & Jacobs, B. C. (2024). Guillain–Barré syndrome. Nature Reviews Disease Primers, 10(1). https://doi.org/10.1038/s41572-024-00580-4

Vancouver

Leonhard SE, Papri N, Querol L, Rinaldi S, Shahrizaila N, Jacobs BC. Guillain–Barré syndrome. Nature Reviews Disease Primers. 2024;10(1). doi:10.1038/s41572-024-00580-4

BibTeX
@article{Leonhard2024,
  author = {Leonhard, Sonja E and Papri, Nowshin and Querol, Luis and Rinaldi, Simon and Shahrizaila, Nortina and Jacobs, Bart C},
  title = {Guillain–Barré syndrome},
  journal = {Nature Reviews Disease Primers},
  year = {2024},
  volume = {10},
  number = {1},
  doi = {10.1038/s41572-024-00580-4}
}
Kostenlos starten →